THE MM-021 CHINA REGISTRATION TRIAL: A PHASE 2 STUDY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN CHINESE RELAPSED/REFRACTORY MYELOMA PATIENTS

被引：0
|
作者：
Hou, J. [1 ]
Du, X. [2 ]
Jin, J. [3 ]
Cai, Z. [3 ]
Chen, F. [4 ]
Zhou, D. [5 ]
Yu, L. [6 ]
Ke, X. [7 ]
Li, X. [8 ]
Wu, D. [9 ]
Meng, F. [10 ]
Ai, H. [11 ]
Zhang, J. [12 ]
Chen, N. [12 ]
Mei, J. [12 ]
Wang, J. [13 ]
机构：
[1] Shanghai Changzheng Hosp, Shanghai, Peoples R China
[2] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[4] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
[5] Beijing Union Med Coll Hosp, Beijing, Peoples R China
[6] 301 Mil Hosp, Beijing, Peoples R China
[7] Peking Univ, Hosp 3, Beijing, Peoples R China
[8] Shanghai Sixth Peoples Hosp, Shanghai, Peoples R China
[9] Suzhou Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[10] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
[11] 307 PLA Hosp, Beijing, Peoples R China
[12] Celgene Corporat, Summit, NJ USA
[13] Changhai Hosp, Shanghai, Peoples R China
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P813
引用
收藏
页码：341 / 341
页数：1
相关论文
共 50 条
  • [1] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Jian Hou
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Dao-bin Zhou
    Li Yu
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Huisheng Ai
    Jingshan Zhang
    Honeylet Wortman-Vayn
    Nianhang Chen
    Jay Mei
    Jianmin Wang
    Journal of Hematology & Oncology, 6
  • [2] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Hou, Jian
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Zhou, Dao-bin
    Yu, Li
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    Wortman-Vayn, Honeylet
    Chen, Nianhang
    Mei, Jay
    Wang, Jianmin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [3] Efficacy and Safety Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment: MM-021 Subgroup Analysis
    Zhou, Dao-Bin
    Yu, Li
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    Wortman-Vayn, Honeylet
    Mei, Jay
    Wang, Jianmin
    Hou, Jian
    BLOOD, 2013, 122 (21)
  • [4] IMPACT OF RENAL IMPAIRMENT ON THE EFFICACY AND SAFETY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): MM-021 TRIAL
    Zhou, D. B.
    Yu, L.
    Du, X.
    Jin, J.
    Cai, Z.
    Chen, F.
    Li, X.
    Wu, D.
    Meng, F.
    Ai, H.
    Zhang, J.
    Wortman-Vayn, H.
    Mei, J.
    Wang, J.
    Hou, J.
    HAEMATOLOGICA, 2014, 99 : 371 - 371
  • [5] IMPACT OF PRIOR THERAPY (TX) ON THE EFFICACY AND SAFETY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): MM-021 TRIAL
    Jin, J.
    Du, X.
    Cai, Z.
    Chen, F.
    Zhou, D. B.
    Yu, L.
    Li, X.
    Wu, D.
    Meng, F.
    Ai, H.
    Wang, J.
    Zhang, J.
    Wortman-Vayn, H.
    Mei, J.
    Hou, J.
    HAEMATOLOGICA, 2014, 99 : 375 - 375
  • [6] Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
    Dao-bin Zhou
    Li Yu
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Huisheng Ai
    Jingshan Zhang
    Dena DeMarco
    Nianhang Chen
    Jay Mei
    Jianmin Wang
    Jian Hou
    International Journal of Hematology, 2015, 101 : 569 - 577
  • [7] Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
    Zhou, Dao-bin
    Yu, Li
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    DeMarco, Dena
    Chen, Nianhang
    Mei, Jay
    Wang, Jianmin
    Hou, Jian
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 569 - 577
  • [8] Pharmacokinetics (PK) of Lenalidomide When Administered Alone or in Combination with Dexamethasone in Chinese Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): The MM-021 Trial
    Chen, Nianhang
    Thou, Dao-bin
    Yu, Li
    Mei, Jay
    Liu, Liangang
    Wang, Xiaomin
    Wortman-Vayn, Honeylet
    Hou, Jian
    BLOOD, 2012, 120 (21)
  • [9] Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma
    Seok Jin Kim
    Danbee Kang
    Yong Park
    Yeung-Chul Mun
    Kihyun Kim
    Jin Seok Kim
    Chang-Ki Min
    Juhee Cho
    Supportive Care in Cancer, 2021, 29 : 4969 - 4977
  • [10] A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    Moreau, Philippe
    Reece, Donna E.
    White, Darrell J.
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn
    Singhal, Anil K.
    Richardson, Paul G.
    BLOOD, 2011, 118 (21) : 141 - 142
12345